Omega Diagnostics awarded grant for HIV test

Omega Diagnostics has been awarded a grant of up to 150,000 pounds from Scottish Enterprise to help scale up manufacturing facilities for the company's new CD4 test for monitoring HIV positive patients.

Omega Diagnostics has been awarded a grant of up to 150,000 pounds from Scottish Enterprise to help scale up manufacturing facilities for the company's new CD4 test for monitoring HIV positive patients.

The facility will be located at the company's headquarters in Alva, Central Scotland and the grant will be payable in three installments dependent on the attainment of employment targets and capital expenditure.

The project is split into two phases: the first phase being conversion of a part of the existing premises to meet initial customer demand and a second phase to allow further scale up to meet future anticipated demand. It is expected that a first instalment of £32,000 will be received in the current financial year.

Dr Robin Campbell, healthcare analyst, at House Broker Seymour Pierce has a 'buy' recommendation with a price target of 25p on the stock. He commented that CD4 testing is a bottleneck in starting anti-HIV drug therapy, particularly in emerging economies with poorly funded healthcare systems.

Therefore, a convenient, low-cost point-of-care (POC) test would be a boon for healthcare workers in helping identify HIV-positive sufferers with declining CD4 counts - the World Health Organisations's guideline is for anti-HIV drug therapy for those with counts below 350 cells/microlitre of blood.

He added: "Omega Diagnostic's Visitect CD4 test (one drop from a finger prick, result in 40 minutes) is set to be the only lower cost, low complexity POC test on the market. ODX plans to make commercial quantities of product for evaluation by December this year. There are over 20m HIV-positive individuals in developing countries."

CM

Recommended

The ten highest dividend yields in the FTSE 100
Income investing

The ten highest dividend yields in the FTSE 100

Rupert Hargreaves takes a look at the companies with the highest dividend yields in the UK’s blue-chip index
6 Feb 2023
The outlook for Shell shares is mixed, despite bumper profits
Energy stocks

The outlook for Shell shares is mixed, despite bumper profits

With profits surging, it looks as if Shell is on a roll, but the company’s growth from here is hard to see as Rupert Hargreaves explains.
6 Feb 2023
The top funds to invest in
Funds

The top funds to invest in

As market volatility and recessionary fears continue, here are the most popular funds, stocks and trusts investors are putting their money into accord…
2 Feb 2023
The top ten dividend stocks in the FTSE 250
Share tips

The top ten dividend stocks in the FTSE 250

The average FTSE 250 dividend yield is around 4%, but many stocks yield much more. Rupert Hargreaves picks the best FTSE 250 stocks for income investo…
17 Jan 2023

Most Popular

NS&I brings back one-year fixed bonds with highest rates since 2010
Personal finance

NS&I brings back one-year fixed bonds with highest rates since 2010

NS&I’s one-year fixed bonds are back on sale after being pulled off the market in 2019 - but is the rate any good?
1 Feb 2023
How to invest like an ISA millionaire
Investments

How to invest like an ISA millionaire

We reveal the top funds and trusts ISA millionaires pumped their money into
6 Feb 2023
The best one-year fixed savings accounts - February 2023
Savings

The best one-year fixed savings accounts - February 2023

Earn almost 5% on one-year fixed savings accounts.
6 Feb 2023